Chapters
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
|
Adalimumab | ||
|
Asacol M/R 400mg, 800mg | ||
|
Azathioprine tablets |
ESCA |
|
|
Balsalazide |
Consultant initiation - only when other agents have been ineffective |
|
|
Budesonide (Budenofalk® ) Suppositories |
Specialist recommendation |
|
|
Budesonide 1mg orodispersible tablets (Jorveza®) | ||
|
Budesonide 2mg rectal foam (2mg per 1 metered dose) (Budenofalk®) |
Approved to support the shortage of Colifoam (June 2018) |
|
|
Budesonide 9mg prolonged-release tablets (Cortiment®) | ||
|
Budesonide capsules (Budenofalk capsules 3mg) |
Consultant initiation only |
|
|
Budesonide MMX (Cortiment®) | ||
|
Ciclosporin intravenous |
Hospital only - MHRA specify that oral ciclosporin must be prescribed and dispensed by brand as bioavailability differences exist between brands. |
|
|
Ciclosporin oral |
Hospital only - MHRA specify that oral ciclosporin must be prescribed and dispensed by brand as bioavailability differences exist between brands. |
|
|
Eluxadoline (Truberzi®) |
To be used in line with NICE TA 471. Specialist initiation, and transfer prescribing to GP using RICaD (in development). |
|
|
Etrasimod | ||
|
Filgotinib (Jyseleca®)#1.5 | ||
|
Guselkumab (Tremfya®) |
Please contact mmag@uhb.nhs.uk for advice |
|
|
Hydrocortisone foam (Colifoam) | ||
|
Hydrocortisone injection | ||
|
Hydrocortisone tablets | ||
|
Infliximab | ||
|
Mercaptopurine tablets |
ESCA |
|
|
Mesalazine (Octasa®) |
Octasa is preferred brand of choice |
|
|
Methotrexate tablets (2.5mg) |
ESCA. Methotrexate tablets - use 2.5mg strength only. Methotrexate injection - Metoject is APC preferred brand. Check cytotoxic disposal arrangements locally. |
|
|
Mezavant XL | ||
|
Mirikizumab (Omvoh®) | ||
|
Mirikizumab (Omvoh®) | ||
|
Ozanimod (Zeposia®) | ||
|
Ozanimod (Zeposia®) | ||
|
Pentasa 1g suppositories | ||
|
Pentasa M/R 500mg | ||
|
Prednisolone foam enema | ||
|
Prednisolone retention enema | ||
|
Prednisolone suppositories | ||
|
Prednisolone tablets |
For exacerbations |
|
|
Risankizumab (Skyrizi®) | ||
|
Salofalk foam enema | ||
|
Salofalk granules | ||
|
Sulfasalazine | ||
|
Teduglutide (Revestive®) | ||
|
Tofacitinib (Xeljanz®) | ||
|
Upadacitinib (Rinvoq®)#1.5 | ||
|
Ustekinumab (Stelara®) | ||
|
Vedolizumab |
|